Page 90 - 2019_05-HaematologicaMondo-web

N. Gagelmann et al.
8. Malcovati L, Hellström-Lindberg E, Bowen
D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: rec- ommendations from the European LeukemiaNet. Blood. 2013;122(17):2943- 2964.
9. Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123(15): 2333-2342.
10. Shaffer BC, Ahn KW, Hu ZH, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syn- drome. J Clin Oncol. 2016;34(16):1864-1871.
11. Schanz J, Tüchler H, Solé F, et al. New com- prehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(17): 820-829.
12. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
13. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 1999;94(9):496- 509.
15. Gónen M, Heller G. Concordance probabili- ty and discriminatory power in proportional hazards regression. Biometrika. 2005;92(4): 965-970.
16. Raykar VC, Steck H, Krishnapuram B,
Dehing-Oberije C, Lambin P. On ranking in survival analysis: bounds on the concor- dance index. Presented at the 21 Annual Conference on Neural Information Processing Systems, Vancouver, British Columbia, Canada, December 3-6, 2007.
17. Koenecke C, Göhring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multi-center study of the European Society of Blood and Marrow Transplantation. Haematologica. 2015;100(3):400-408.
18. Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427-2438.
19. Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173-178.
20. Gagelmann N, Ljungman P, Styczynski J, Kröger N. Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a sys- tematic review and meta-analysis. Biol Blood Marrow Transplant. 2018;24(10): 2101-2109.
21. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433-2444.
22. Gagelmann N, Ayuk F, Wolschke C, Kröger
N. Comparison of different rabbit anti-thy- mocyte globulin formulations in allogeneic stem cell transplantation: systematic litera- ture review and network meta-analysis. Biol Blood Marrow Transplant. 2017;23(12): 2184-2219.
23. Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the out- come of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59(4):473-481.
24. Della Porta MG, Gallì A, Bacigalupo A, et al. Clinical effects of driver somatic mutations on the outcomes of patients with myelodys- plastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34(30):3627-3637.
25. Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547.
26. Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome after stem cell transplan- tation. Blood. 2017;129(17):2347-2358.
27. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplan- tation for advanced hematologic malignan- cies. JAMA. 2011;306(17):1874-1883.
28. Kröger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplan- tation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35(19):2157-2164.
936
haematologica | 2019; 104(5)